Triple agonist medications activate GLP-1, GIP, and glucagon receptors simultaneously to improve glucose control, promote weight loss, and enhance overall metabolic health
The combined effect is a steady rise in blood sugar that begins within hours of the first dose and continues for the duration of treatment
8 May 2025 Semaglutide Shows Promise in Treating MASH and Liver Fibrosis Semaglutide significantly improves liver inflammation and fibrosis in MASH patients, offering new hope for clinical management
Learn More Ozempic Semaglutide consultation option for patients interested in GLP-1 support
Peptides are often pitched as a quick way to build muscle, heal injuries, reduce inflammation or appear younger, but many have never been approved for human use and much of their evidence comes from studies in rats
While Ozempic includes the same core ingredient found in some cutting-edge weight loss medications, it is strictly meant for diabetes management and not for weight loss
